Updated Jul 16, 2026
Boyd Peter E. has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $337K.
Peter E. Boyd is the Chief People Officer at Aquestive Therapeutics, Inc., a specialty pharmaceutical company focused on developing products for medical needs, particularly in the Central Nervous System. He has been involved in several SEC filings related to his role within the company.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-07 | AQST | Aquestive Therapeutics, Inc. | F — Tax withholding / forfeiture | 56.8K | $4.18 | $237K |
| 2026-03-11 | AQST | Aquestive Therapeutics, Inc. | S — Open-market sale | 29.8K | $4.17 | $124K |
| 2026-03-11 | AQST | Aquestive Therapeutics, Inc. | A — Grant or award | 80.0K | $0.00 | |
| 2025-12-05 | AQST | Aquestive Therapeutics, Inc. | A — Grant or award | 20.0K | $0.00 | |
| 2025-10-15 | AQST | Aquestive Therapeutics, Inc. | S — Open-market sale | 10.0K | $7.00 | $70K |
| 2025-09-26 | AQST | Aquestive Therapeutics, Inc. | S — Open-market sale | 10.0K | $6.30 | $63K |
| 2025-09-05 | AQST | Aquestive Therapeutics, Inc. | S — Open-market sale | 15.0K | $5.30 | $80K |
Peter E. Boyd is the Chief People Officer at Aquestive Therapeutics, Inc., a specialty pharmaceutical company focused on developing products for medical needs, particularly in the Central Nervous System. He has been involved in several SEC filings related to his role within the company.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 4 open-market sales ($337K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Boyd Peter E. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.